Research programme: cytokine/ceramide inhibitors - Signpath Pharma
Latest Information Update: 06 Sep 2023
Price :
$50 *
At a glance
- Originator Signpath Pharma
- Class
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ventricular arrhythmias
Most Recent Events
- 06 Sep 2023 Preclinical development for Ventricular-arrhythmias(Prevention) is ongoing in USA (IV) (PO) (Signpath Pharma pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Ventricular-arrhythmias(Prevention) in USA (IV)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Ventricular-arrhythmias(Prevention) in USA (PO)